Jennifer Pietenpol

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)

Clinical trial shows efficacy for atezolizumab combined with carboplatin

Shown at Monday’s VICC Annual Scientific Retreat are (front row, from left) Timothy Blackwell, MD, Fabien Maldonado, MD, Denise Aberle, MD, Melinda Aldrich, PhD, MPH, Kim Sandler, MD, (back row, from left) Eric Grogan, MD, MPH, Sudhir Srivastava, PhD, MPH, M. Patricia Rivera, MD, Julien Sage, PhD, David Carbone, MD, PhD, and Scott Hiebert, PhD.

VICC Scientific Retreat focuses on lung cancer

VUMC’s Pietenpol, Shyr named AACR Fellows

Vanderbilt’s Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).

‘Multi-omics’ reveals treatment option for breast cancer subtype

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

1 2 3 5